Reviewing GlycoMimetics Inc. (GLYC)’s and Neptune Wellness Solutions Inc. (NASDAQ:NEPT)’s results

GlycoMimetics Inc. (NASDAQ:GLYC) and Neptune Wellness Solutions Inc. (NASDAQ:NEPT) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GlycoMimetics Inc. N/A 0.00 43.62M -1.13 0.00
Neptune Wellness Solutions Inc. N/A 0.00 N/A -0.07 0.00

In table 1 we can see GlycoMimetics Inc. and Neptune Wellness Solutions Inc.’s top-line revenue, earnings per share and valuation.


Table 2 represents GlycoMimetics Inc. (NASDAQ:GLYC) and Neptune Wellness Solutions Inc. (NASDAQ:NEPT)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
GlycoMimetics Inc. 0.00% -21.7% -20.9%
Neptune Wellness Solutions Inc. 0.00% 0% 0%

Analyst Recommendations

The Recommendations and Ratings for GlycoMimetics Inc. and Neptune Wellness Solutions Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
GlycoMimetics Inc. 0 0 1 3.00
Neptune Wellness Solutions Inc. 0 0 0 0.00

GlycoMimetics Inc.’s upside potential is 109.24% at a $24 consensus price target.

Insider & Institutional Ownership

Institutional investors held 0% of GlycoMimetics Inc. shares and 17.71% of Neptune Wellness Solutions Inc. shares. About 0.2% of GlycoMimetics Inc.’s share are held by insiders. On the other hand, insiders held about 23.66% of Neptune Wellness Solutions Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
GlycoMimetics Inc. -6.61% -21.96% -24.01% -40.46% -24.49% -36.09%
Neptune Wellness Solutions Inc. -8.44% -24.68% -22.89% 17.2% 104.9% 24.15%

For the past year GlycoMimetics Inc. has -36.09% weaker performance while Neptune Wellness Solutions Inc. has 24.15% stronger performance.


Neptune Wellness Solutions Inc. beats on 5 of the 7 factors GlycoMimetics Inc.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Neptune Technologies & Bioressources Inc., a nutrition products company, focuses on providing nutrition solutions, including specialty ingredients and consumer brands. The company develops solutions available in various delivery forms. It also offers various specialty ingredients, including premium krill oil and other marine oils, as well as seed oils. The company sells its premium krill oil under the OCEANO3 brand directly to consumers through in Canada and the United States. In addition, Neptune Technologies & Bioressources Inc. is pursuing opportunities in the prescription drug markets, through its subsidiary, Acasti Pharma Inc., that focuses on the research, development, and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. The company was founded in 1925 and is headquartered in Laval, Canada.